Search Bar & Filters
Found 9 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating AZD0780, an oral PCSK9 inhibitor, in a phase 3 randomized, double-blind, placebo-controlled study to assess its effect on reducing major adverse cardiovascular events in patients with established atherosclerotic cardiovascular disease ASCVD or those at high risk for a first ASCVD event. The study compares AZD0780 with a placebo and is event-driven, focusing on time to first cardiovascular events over approximately 54 months. Participants will be randomly assigned to receive either oral AZD0780 once daily or a matching placebo once daily. The study treatment continues from randomization until the primary analysis censoring date, followed by a study closure visit which marks the final visit for each participant. Background lipid-lowering therapy is maintained and expected to achieve significant LDL cholesterol reduction. The study design includes parallel treatment groups with quadruple masking to ensure unbiased results. During the study, participants attend regular visits for monitoring and assessments over a period that can last up to about 54 months. Researchers will measure the time to first major cardiovascular events including heart attack, stroke, urgent coronary revascularization, cardiovascular death, and other related outcomes. Safety and efficacy are carefully monitored through clinical evaluations, laboratory tests, and patient follow-up until study completion.
Actively Recruiting
Researchers are evaluating two forms of buprenorphine treatment for Veterans with moderate to severe opioid use disorder OUD. The study compares a long-acting injectable buprenorphine given every 28 days with the standard daily sublingual buprenorphine. This open-label, randomized trial involves 952 Veterans over a 7-year recruitment period and follows them actively for 52 weeks, with additional passive follow-up for up to 10 years. The study also examines effects on substance use, overdose rates, infectious disease status, psychiatric symptoms, housing, dental health, and cost-effectiveness. Participants are first inducted on daily sublingual buprenorphine following SAMHSA guidelines. After reaching a target dose between 4 and 32 mg within 45 days, they are randomized 11 to either continue daily sublingual doses or receive a monthly injectable buprenorphine dose of 300 mg or 100 mg if needed. Study visits occur weekly for the first month, then every two weeks up to week 52, with medication management provided at each visit. Both treatments are administered under clinical supervision with dosing adjustments as needed. Throughout the study, participants complete self-reported opioid use and provide urine samples biweekly. Researchers collect data on retention in treatment, opioid abstinence, overdose events, infectious disease testing, healthcare utilization, craving, psychiatric symptoms, criminal justice involvement, and dental quality of life. After one year of active participation, administrative records are reviewed for ongoing outcomes for up to 10 years. This comprehensive monitoring aims to provide long-term insights into treatment effectiveness and patient well-being.
Actively Recruiting
Researchers are evaluating the addition of cemiplimab, an immunotherapy drug that blocks the PD-1 pathway to help the immune system attack tumor cells, to the usual treatment of docetaxel and ramucirumab for patients with stage IV or recurrent non-small cell lung cancer NSCLC who have previously been treated with platinum chemotherapy and immunotherapy. This phase IIIII randomized trial aims to compare overall survival and other outcomes between the two treatment approaches, including progression-free survival, response rates, and safety. Participants are randomly assigned to one of two groups. One group receives dexamethasone orally, ramucirumab intravenously, and docetaxel intravenously every 21 days. The other group receives the same treatment plus cemiplimab intravenously every 21 days. Treatment cycles continue as long as there is no disease progression or unacceptable side effects. Throughout the study, participants have blood samples collected and undergo CT or MRI scans to monitor disease status. During the study, participants will have regular assessments including tumor imaging and blood tests to track treatment effects and side effects. After completing treatment, participants are followed every 3 to 6 months for up to 3 years to monitor overall survival and disease progression. The study also collects samples for future research on tumor DNA. Total participation can last several years including treatment and follow-up periods.
Actively Recruiting
Researchers are investigating whether combining chemotherapy with the immunotherapy drug pembrolizumab improves overall survival compared to pembrolizumab alone in older adults aged 70 and above with advanced stage IIIB-IV non-small cell lung cancer. This phase III trial focuses on a vulnerable population and aims to evaluate survival, disease progression, treatment response, toxicity, quality of life, and other health factors. The study also explores how gut microbes and geriatric assessments relate to treatment outcomes. Participants are randomly assigned to one of two groups. In the first group, patients receive pembrolizumab intravenously every 21 days for four cycles, followed by maintenance doses every 21 or 42 days for up to two years if there is no disease progression or severe side effects. In the second group, patients receive pembrolizumab plus a chemotherapy regimen chosen by the investigator, given intravenously on specific schedules for four cycles, followed by the same pembrolizumab maintenance as the first group. Imaging tests like MRI, CT, and PET scans are done at the start and throughout treatment. During the study, participants undergo regular clinical assessments, imaging, and laboratory tests to monitor their cancer and overall health. Follow-up visits occur every three months for up to two years and then every six months until five years after starting treatment. Researchers measure overall survival, progression-free survival, response rates, side effects, and quality of life. The study also collects patient-reported information and evaluates safety and tolerability over time.
Actively Recruiting
Researchers are evaluating a master screening protocol called Lung-MAP for patients with previously treated non-small cell lung cancer. This phase IIIII trial aims to develop a genomic screening method for large cancer populations and assign participants to appropriate sub-studies based on specific cancer biomarkers. The goal is to compare new targeted therapies designed to block cancer growth or spread with standard care, including sub-studies for patients not eligible for biomarker-driven treatments. The study involves screening patient specimens to determine eligibility for various biomarker-driven or non-matched sub-studies within the Lung-MAP umbrella protocol. This is a screening study without direct interventions instead, patients are assigned to different treatment sub-studies, each operating independently. The protocol also includes an optional ancillary study evaluating attitudes about the return of somatic mutation findings suggestive of germline mutations. Participants provide tumor tissue for biomarker testing, including molecular profiling and PD-L1 analysis, and may submit fresh biopsies and blood samples for circulating tumor DNA testing. Researchers will monitor screening success rates up to three years and collect patient and physician feedback on genetic findings. Participation involves signing informed consent, providing smoking history, and possibly completing surveys. The study duration and assessments vary depending on sub-study assignment and patient progression.
Actively Recruiting
Researchers are evaluating methods to improve monitoring of early-stage non-muscle invasive bladder cancer by replacing some invasive cystoscopy procedures with urine testing. This phase 2 randomized trial involves 240 patients and compares urinary symptoms, discomfort, anxiety, complications, cancer recurrence, and progression among three groups using different surveillance approaches. Participants are randomly assigned to one of three groups frequent cystoscopy, Xpert Bladder Cancer Monitor urine test, or Bladder EpiCheck urine test. The frequent cystoscopy group undergoes cystoscopy at 6, 12, 18, and 24 months. The Xpert urine test group has urine tests and doctor check-ups at 6 and 18 months, with cystoscopies at 12 and 24 months. The EpiCheck urine test group follows the same schedule as the Xpert group with urine tests at 6 and 18 months and cystoscopy at 12 and 24 months. The total study duration is 24 months. Participants will complete quality of life questionnaires 1 to 3 days after surveillance visits at 3, 6, 12, 18, and 24 months. Researchers will monitor urinary quality of life, number of invasive procedures, anxiety, complications, and cancer outcomes. The study includes regular doctor visits and urine tests or cystoscopy procedures depending on group assignment, with careful tracking of participant experiences over two years.
Actively Recruiting
This research focuses on Veterans at high risk of suicide who have received acute psychiatric treatment in non-VA settings affiliated with the VA in Northern New England. It evaluates whether the VA Brief Intervention and Contact Program VA BIC, a suicide prevention strategy tailored for Veterans, can reduce suicidal thoughts and behavior compared to standard care alone. The study is significant because little is known about preventing suicide in Veterans treated outside VA settings, addressing a critical gap in suicide prevention efforts. Participants will be randomly assigned to receive either the VA BIC intervention plus standard care or standard care alone. VA BIC involves a one-on-one, one-hour personalized educational session on suicide prevention that includes motivational interviewing techniques. After this session, participants receive seven follow-up contacts from a trained mental health provider who monitors symptoms, checks treatment adherence, reviews safety plans, and supports well-being. Both groups continue to have access to standard care provided after mental health discharge. Participants will be assessed at baseline and followed up at three, six, and nine months to measure suicidal ideation using the Beck Scale for Suicidal Ideation, mental health care engagement, social connectedness, coping abilities, and suicide attempts. The study uses an assessor-blinded, randomized controlled design to compare outcomes between the two groups. The total participation lasts at least nine months, with safety and outcome monitoring throughout this period.
Actively Recruiting
Researchers are evaluating a combination therapy for adults with newly diagnosed multiple myeloma not intended for early autologous transplantation. This phase III trial compares a four-drug regimen including daratumumab, bortezomib, lenalidomide, and dexamethasone to a three-drug regimen of daratumumab, lenalidomide, and dexamethasone. The study aims to determine if adding bortezomib improves overall survival and progression-free survival in patients with different minimal residual disease statuses, while also assessing side effects and patient-reported outcomes. All participants first receive standard induction therapy with daratumumab given subcutaneously on specific days, lenalidomide orally daily for 21 days, and dexamethasone orally on certain days, repeated every 28 days for 9 cycles. After induction, patients are randomly assigned to one of two consolidation and maintenance arms one adding bortezomib to the consolidation phase followed by maintenance with daratumumab and lenalidomide, and the other continuing with daratumumab, lenalidomide, and dexamethasone for consolidation and maintenance. Treatments continue in cycles of 28 days unless disease progresses or unacceptable side effects occur. During the study, participants undergo various assessments including bone marrow aspirates, blood tests, imaging with PETCT scans, and patient-reported quality of life evaluations. Researchers monitor overall survival, progression-free survival, response rates, adverse events, and neuropathy symptoms over periods up to 15 years. Follow-up visits occur every 3 months for up to 2 years, then less frequently, ensuring long-term monitoring of treatment effects and safety.
Actively Recruiting
Researchers are studying how repetitive Transcranial Magnetic Stimulation rTMS may improve symptoms of posttraumatic stress disorder PTSD in veterans. The study aims to understand the effects of rTMS on brain activity and systemic inflammation related to PTSD by evaluating changes in the limbic system and inflammatory markers. This pilot study involves adults aged 19 to 70 who have moderate to severe PTSD and are eligible for VA healthcare. Participants receive ten 40-minute sessions of low frequency rTMS 1Hz targeting the right dorsolateral prefrontal cortex over 2 to 4 weeks. During the study, participants undergo functional MRI fMRI scans to observe brain activity changes and provide breath and blood samples to assess inflammation. This open-label trial evaluates the effect of rTMS without a comparison group. Throughout the study, participants are assessed for PTSD symptom frequency and intensity using the CAPS-5 and PCL-5 questionnaires from enrollment to three months after treatment. Depression symptoms are also measured using a self-reported inventory. Participants provide consent, undergo motor threshold testing, and are monitored for safety. The total study duration includes treatment and follow-up assessments lasting up to three months.